Jae Seok Lee

Jae Seok Lee

Auto-generated profile, based on publicly available information

Jae Seok Lee

Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
PHPa Hong
Pa Hong
JLJae Seok Lee
Jae Seok Lee
KLKyung Soo Lee
Kyung Soo Lee
Hong P, et al. Korean J Radiol. 2022 Jun;23(6):688-690. https://doi.org/10.3348/kjr.2022.0156

15 January 2024 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
JLJae Seok Lee
Jae Seok Lee
EKEun Kyung Kim
Eun Kyung Kim
KKKyung A Kim
Kyung A Kim
HSHyo Sup Shim
Hyo Sup Shim
Purpose We investigated the clinical impact of genomic and pathway alterations in stage I epidermal growth factor receptor (EGFR)–mutant lung adenocarcinomas, which have a high recurrence rate despite complete surgical resection.Materials and Methods Out of the initial cohort of 257 patients with completely resected stage I EGFR-mutant lung adenocarcinoma, tumor samples from 105 patients were subjected to analysis using large-panel next-generation sequencing. We analyzed 11 canonical oncogenic pathways and determined the number of pathway alterations (NPA). Survival analyses were performed based on co-occurring alterations and NPA in three patient groups: all patients, patients with International Association for the Study of Lung Cancer (IASLC) pathology grade 2, and patients with recurrent tumors treated with EGFR–tyrosine kinase inhibitor (TKI).Results In the univariate analysis, pathological stage, IASLC grade, TP53 mutation, NPA, phosphoinositide 3-kinase pathway, p53 pathway, and cell cycle pathway exhibited significant associations with worse recurrence-free survival (RFS). Moreover, RPS6KB1 or EGFR amplifications were linked to a poorer RFS. Multivariate analysis revealed that pathologic stage, IASLC grade, and cell cycle pathway alteration were independent poor prognostic factors for RFS (p=0.002, p < 0.001, and p=0.006, respectively). In the grade 2 subgroup, higher NPA was independently associated with worse RFS (p=0.003). Additionally, in patients with recurrence treated with EGFR-TKIs, co-occurring TP53 mutations were linked to shorter progression-free survival (p=0.025).Conclusion Genomic and pathway alterations, particularly cell cycle alterations, high NPA, and TP53 mutations, were associated with worse clinical outcomes in stage I EGFR-mutant lung adenocarcinoma. These findings may have implications for risk stratification and the development of new therapeutic strategies in early-stage EGFR-mutant lung cancer patients.

4 September 2022 in Journal of the Korean Society of Radiology
Verified
Journal Article
Open access
PDF file
PHPa Hong
Pa Hong
JLJae Seok Lee
Jae Seok Lee
KLKyung Soo Lee
Kyung Soo Lee
홍파, et al. J Korean Soc Radiol. 2022 Sep;83:e70. https://doi.org/10.3348/jksr.2022.0057